The pharmaceutical industry is increasingly under pressure to bring innovative therapies to market quickly.
Early clinical data, often derived from Phase I and II trials, can be used to expedite launch timelines. However, the use of early data necessitates careful navigation of scientific, regulatory, and commercial hurdles. In Europe, understanding the acceptance of early data by health technology assessment (HTA) bodies such as National Institute for Health and Care Excellence (NICE) (UK), Haute Autorité de Santé (HAS) (France), and Gemeinsamer Bundesausschuss (G-BA) (Germany) is crucial for reimbursement and market access.
2.1 France
HAS places a strong emphasis on the added clinical benefit of new treatments compared to existing alternatives. As a result, there is a preference for head-to-head clinical trials to demonstrate superiority, making it challenging to launch products based on early-phase clinical data. Without direct comparators, establishing clear clinical superiority over the standard of care can be difficult. While indirect treatment comparisons (ITCs) may offer valuable insights in the absence of direct data, the HAS Transparency Committee often views them with skepticism due to concerns about potential bias. However, single-arm phase II data have been accepted for approval and reimbursement in cases where no therapeutic alternatives exist, and a substantial response rate is demonstrated.
Despite these challenges, several factors support the use of early data in France. The Early Access Program (EAP), formerly known as the Temporary Authorization for Use (ATU), allows patients with serious, rare, or debilitating diseases to access innovative therapies before full marketing authorization. This program is particularly beneficial for treatments addressing significant unmet medical needs, ensuring timely patient access to potentially life-saving medications. Additionally, HAS increasingly incorporates patient-reported outcomes and real-world evidence (RWE) into its evaluations. This shift strengthens the case for products launched with early data, as pharmaceutical companies can leverage conditional reimbursement agreements to negotiate market entry while additional data is collected. These agreements allow treatments to reach patients sooner, with the understanding that further evidence will be gathered to confirm their efficacy and safety.
2.2 UK
Launching a treatment in the UK with early clinical data presents several challenges, primarily due to the stringent requirements imposed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the NICE. Both agencies demand robust clinical and cost-effectiveness evidence for reimbursement, which can be difficult to generate in the early stages of a product’s lifecycle. NICE’s rigorous evaluation process further complicates market access, often leading to delays. Even when early data is considered, the need for additional RWE post-launch can create financial and operational burdens for pharmaceutical companies. Additionally, orphan drugs, while eligible for incentives, undergo heightened scrutiny due to their typically high costs, making reimbursement negotiations more complex.
Despite these challenges, the UK offers several opportunities for companies seeking early market entry. The MHRA provides accelerated approval pathways, such as the Innovative Licensing and Access Pathway (ILAP), designed to facilitate faster approval of promising therapies. These initiatives can help bridge the gap between early clinical data and full market access, allowing patients to benefit from innovative treatments sooner. Furthermore, NICE is increasingly integrating RWE into its reimbursement decisions, which provides an avenue to strengthen the case for therapies launched with limited early-phase data. This shift acknowledges the evolving nature of evidence generation and aligns with global trends toward incorporating real-world patient outcomes.
2.3 Germany
Launching a treatment in Germany with early clinical data presents several challenges due to the country’s stringent HTA process. The G-BA conducts a rigorous early benefit assessment under the AMNOG process, requiring strong evidence of added value compared to the standard of care. Limited early data can make it difficult to demonstrate clear clinical superiority, which in turn affects pricing negotiations with statutory health insurers. Products which fail to demonstrate improvement versus standard of care are deemed will be assigned a benefit rating of additional benefit not proven. Since reimbursement and pricing are directly tied to the outcome of the AMNOG process, companies face financial uncertainty when launching with early-phase data.
Despite these challenges, Germany offers significant opportunities for companies looking to launch with early data. One major advantage is the country’s policy of immediate market access upon EMA approval, allowing manufacturers to generate revenue while undergoing the AMNOG assessment. This reduces delays in patient access and provides an opportunity to strengthen the evidence base during the reimbursement process. In addition, orphan drugs, due to the challenges of running head-to-head trials in small patient populations, are initially granted a non-quantifiable additional benefit without undergoing a full review up to a sales threshold of 30 million EUR per year. Once this threshold is exceeded, a full HTA review is required. This creates an incentive for smaller-scale, high-impact therapies to enter the market earlier, ensuring access for patients with rare diseases while allowing manufacturers time to generate additional data to support pricing and reimbursement negotiations.
Conclusion
While launching pharmaceutical products based on early data presents challenges, strategic planning and proactive stakeholder engagement can maximize opportunities. Companies that successfully balance speed, regulatory compliance, and data generation will be well-positioned for sustainable success in the evolving pharmaceutical landscape. In Europe, navigating HTA requirements and leveraging RWE is crucial for long-term market success.
About the author
With over nine years of experience in global market access and health economics and outcomes research (HEOR), Patrick works closely with our clients to navigate complex healthcare landscapes. He has supported pharmaceutical, biotech, and medical device companies by delivering insights through payer and patient surveys, literature reviews, value demonstration materials, and external publications.
Patrick has led the development of economic models for various oncology indications, ensuring our clients can effectively demonstrate the value of their innovations. His expertise spans biologics, vaccines, and medical devices, helping clients assess market access challenges, refine value propositions, and generate robust evidence to support product positioning.
Committed to delivering meaningful healthcare solutions, Patrick collaborates with global stakeholders to optimise market access strategies and drive successful outcomes for our clients.
Navigate market access challenges and maximise the impact of your innovations. Get in touch to learn how our team of consultants can support your success.
